ESR1 and metastatic neoplasm: Of these, we excluded cases with de novo metastatic disease (n = 14), those missing ER or PR status (n = 82), and those with ER positivity < 10% (n = 34), leaving 707 cases left for analysis in our study cohort (Table 1).